Announcing the International Prognostic Score for NLPHL (LP-IPS) in @JCO_ASCO, the largest study of NLPHL to date. Congratulations to our founders Drs. @michaelsbinkley & @JamieFlerlage and the GLOW team on this high-impact publication. #NLPHLsm #lymsm

The LP-IPS prognostic score for NLPHL, developed through the @glow_nlphl consortium, was just cited in a new review published by Drs. Eichenauer & Borchmann. #lymsm #NLPHLsm

For those interested in clinical trials, there is a trial-in-progress being presented at the @ASH_hematology #ASH24 annual meeting this weekend by Dr. Steiner on rituximab versus mosunetuzumab for either untreated Stage IB-IV NLPHL or relapsed NLPHL of any stage. #lymsm #NLPHLsm

An important scientific workshop this Friday at #ASH24 on germline TET2 mutations predisposing patients to the development of NLPHL. #lymsm #NLPHLsm

RT @majorajay: New consensus algorithm for the treatment of NLPHL by @graham74GC & @chanyooncheah, now published @Haematologica. Looking fo…

Our @glow_nlphl consortium was mentioned in a recent publication by Drs. @graham74GC & @chanyooncheah about advances in the risk stratification and treatment of NLPHL. cc @Haematologica #NLPHLsm #lymsm

RT @michaelsbinkley: 2nd GLOW summit was a resounding success thanks to Monica Palese and all GLOW members and collaborators. The thousands…

RT @majorajay: UK NLPHL experience #ISHL13: - 203 pts, 64% early-stage - 19% W&W, 41% of those req'd tx median 1.7 yrs later - no survival…

RT @majorajay: Nordic NLPHL experience @glimelius #ISHL13: - 752 pts, f/u 8-10 yrs - 19% of cohort relapsed at median 2.9-4.5 yrs - 4% tran…

New study presented at #ISHL13 by Dr. @IljaKalashnikov to clarify the tumor microenvironment in NLPHL. #lymsm #NLPHLsm

RT @majorajay: NLPHL-specific GEP development #ISHL13 @michaelsbinkley: - GEP subtypes do not correlate with morphologic variant patterns -…

Clinical trial protocol presented by Dr. Steiner at #ISHL13: randomized trial of rituximab versus mosunetuzumab in first-line stage IB to IV NLPHL. #lymsm #NLPHLsm

RT @glimelius: Thanks to good collaboration within the Nordic group #ISHL13 #lymsm we could do a study on >700 #NLPHL patients. A little la…

RT @graham74GC: Many congratulations to @RSalvaris who has written a very nice review on the fascinating, controversial and still understud…

RT @RSalvaris: Really excited to share our review article on updates in the biology, prognostication and treatment of nodular lymphocyte pr…

RT @majorajay: Now published @JCO_ASCO: the newly-developed NLPHL prognostic score (LP-IPS), an international effort by the @glow_nlphl con…

Our multicenter, international validation study of the LP-IPS prognostic score in NLPHL has now been published in @JCO_ASCO. This study is a testament to the potential for cross-disciplinary team science research through @glow_nlphl. #lymsm #NLPHLsm

RT @majorajay: #NLPHL case for #lymsm: teenager dx with Stage IIA (cervical, axillary) NLPHL 2.5 years ago. At that time, received ritux x…

We're excited to launch our new and improved website! Head over to to learn about our international research consortium striving to improve the diagnosis and treatment of NLPHL. #lymsm #NLPHLsm

RT @vit_prochazka: CASE: Hodgkin community, pls comment: 18 y.o. lady, NLPHL (subtype D), CS IIA (neck bilat) biopsy from the largest (5cm)…

RT @JamieFlerlage: Thankful for the chance to share our work on GLOW with the global community and our friends at @SIOPEurope!! Thank you E…